Gemini Therapeutics is using precision medicine in the heterogeneous disease, dry AMD to identify patients in specific high-risk genetically defined subpopulations.
We are able to use genetics and biology to identify genetic variants and define subpopulations of patients suffering from AMD, the number one cause of irreversible blindness in the U.S. and the EU.
We integrate genetic, biological, and clinical information to identify high-risk, genetically defined subpopulations present within AMD. We are able to identify, functionally evaluate and characterize the genetic variants associated with AMD to define their roles in disease pathogenesis. This includes custom genetic assays, novel biomarkers, and natural history studies.
Our primary focus is to drug the specific target and to utilize whatever the most relevant therapeutic modality is to accomplish that goal. This strategy has resulted in a broad and diverse pipeline, including recombinant proteins, monoclonal antibodies and gene therapies.